EVOMMUNE INC SEC Filings

Evommune, Inc. entered into a securities purchase agreement for a private placement of 4,494,279 shares of common stock at $27.88 per share, for expected gross proceeds of about $125 million before expenses. The deal is with a select group of new and existing institutional and healthcare-focused investors and is expected to close on or about February 17, 2026, subject to customary conditions.

Evommune plans to use the net proceeds to advance its clinical development programs and for general corporate purposes. The company also granted investors registration rights, committing to file a Form S-1 to register the resale of these shares and to keep that registration effective until the shares are sold or freely tradable.

Evommune, Inc. reported positive top-line results from a randomized, double-blind, placebo-controlled Phase 2a trial of EVO301 in adults with moderate-to-severe atopic dermatitis. The 70-patient study used two intravenous doses of 5 mg/kg on day 1 and day 28 over 12 weeks.

The trial met its primary endpoint based on a Bayesian analysis of EASI score improvement, with 99.8% of the posterior distribution showing at least an 8% benefit over placebo, far above the 75% success criterion. Using a frequentist method, EVO301 showed statistically significant EASI improvements versus placebo at weeks 4, 8 and 12 with p<0.01.

Placebo-adjusted EASI improvements were 34% at week 8 and 33% at week 12, and 23% of EVO301-treated patients achieved vIGA-AD 0/1 at week 12 compared with 0% on placebo. EVO301 was well tolerated, with no related serious or severe adverse events, no treatment-related discontinuations, and no meaningful safety imbalances. Evommune plans a Phase 2b dose-ranging trial in atopic dermatitis using a subcutaneous formulation and is evaluating additional indications, including ulcerative colitis.

Evommune, Inc. insider and 10% owner reports a share purchase. A reporting person who is both a director and 10% owner of Evommune, Inc. (EVMN) disclosed buying 1,000 shares of common stock on 12/19/2025 at a price of $17.35 per share through a family trust.

After this transaction, 4,026 shares of common stock are reported as indirectly owned through the family trust. Additional indirect holdings are reported as 1,441,032 shares through NFLS Delta III Limited, 1,632,441 shares through Pivotal bioVenture Partners Fund I, L.P., and 294,502 shares through Pivotal bioVenture Partners Fund II, L.P. In each case, the reporting person disclaims beneficial ownership beyond their proportionate pecuniary interest.

Evommune, Inc. reported an equity award to one of its senior leaders. On 12/08/2025, a reporting person who serves as both a director and Chief Medical Officer received an employee stock option to buy 100,000 shares of Evommune common stock at an exercise price of $18.44 per share. The option expires on 12/08/2035.

One fourth of the option shares will vest on December 8, 2026, and the remaining shares will vest in 36 equal monthly installments after that date, as long as the reporting person continues to provide service. After this grant, the reporting person beneficially owns 100,000 derivative securities directly.

Evommune, Inc. President and CEO, who is also a director, reported an automatic share withholding related to equity compensation. On 12/09/2025, 28,138 shares of Evommune common stock were disposed of at a reported price of $17.84 per share. The filing explains that these shares were withheld to cover the reporting person's tax withholding obligations upon the settlement of restricted stock units, rather than an open-market sale. After this tax withholding event, the reporting person beneficially owns 654,683 shares of Evommune common stock in direct ownership.

Evommune, Inc. reported an insider equity transaction by its Chief Scientific Officer, who is an officer of the company and files individually. On 12/09/2025, the officer had 7,513 shares of common stock withheld, coded as an "F" transaction, at a price of $17.84 per share. According to the explanation, these shares were withheld to cover the officer’s tax obligations arising from the settlement of restricted stock units, a common administrative step when stock awards vest.

After this tax withholding event, the officer beneficially owned 49,578 shares of Evommune common stock in direct ownership. The filing indicates this was not part of a trading plan under Rule 10b5-1, and does not involve any derivative securities such as options or warrants.

Evommune, Inc. executive Gregory S. Moss, the company’s Chief Business & Legal Officer, reported an insider transaction involving company stock. On 12/09/2025, 13,624 shares of Evommune common stock were withheld at a price of $17.84 per share to cover his tax withholding obligations tied to the settlement of restricted stock units. After this transaction, he directly beneficially owned 60,835 shares of common stock and indirectly held 3,175 additional shares through a family trust in which he serves as trustee.

Evommune, Inc. executive vice president of operations reported an insider equity transaction. On 12/09/2025, the officer had 5,074 shares of Evommune common stock withheld, coded as an "F" transaction, at a price of $17.84 per share. The filing explains these shares were withheld to satisfy tax withholding obligations tied to the settlement of restricted stock units, rather than being an open-market sale. After this tax-related transaction, the reporting person beneficially owned 67,794 shares of Evommune common stock directly.

Evommune, Inc. reported an insider equity transaction by its Chief Financial Officer on a Form 4. On 12/09/2025, 13,290 shares of common stock were withheld at a price of $17.84 per share to cover the officer’s tax obligations tied to the settlement of restricted stock units. After this tax withholding event, the CFO directly beneficially owned 62,510 shares of Evommune common stock.